Cetrorelix
Active ingredient: Cetrorelix Acetate
In short: Cetrorelix Acetate for Injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.
What is Cetrorelix used for?
Cetrorelix Acetate for Injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.
âš Boxed warning (FDA's strongest warning)
Cetrorelix acetate for injection should be prescribed by physicians who are experienced in fertility treatment. Before starting treatment with cetrorelix acetate, pregnancy must be excluded .
Cetrorelix dosage
Ovarian stimulation therapy with gonadotropins (FSH, hMG) is started on cycle Day 2 or 3. The dose of gonadotropins should be adjusted according to individual response. Cetrorelix acetate for injection 0.25 mg may be administered subcutaneously once daily during the early- to mid-follicular phase.
Cetrorelix acetate for injection 0.25 mg is administered on either stimulation day 5 (morning or evening) or day 6 (morning) and continued daily until the day of hCG administration.
When assessment by ultrasound shows a sufficient number of follicles of adequate size, hCG is administered to induce ovulation and final maturation of the oocytes. No hCG should be administered if the ovaries show an excessive response to the treatment with gonadotropins to reduce the chance of developing ovarian hyperstimulation syndrome (OHSS).
Cetrorelix acetate for injection 0.25 mg can be administered by the patient herself after appropriate instructions by her doctor.
Directions for using cetrorelix acetate for injection 0.25 mg with the enclosed needles and prefilled syringe:
Wash hands thoroughly with soap and water.
Flip off the plastic cover of the vial and wipe the aluminum ring and the rubber stopper with an alcohol swab.
Twist the injection needle with the yellow mark (20-gauge) on the prefilled syringe.
Push the needle through the center of the rubber stopper of the vial and slowly inject the solvent into the vial.
Leaving the syringe in the vial, gently swirl the vial until the solution is clear and without residues. Avoid forming bubbles.
Draw the total contents of the vial into the syringe. If necessary, invert the vial and pull back the needle as far as needed to withdraw the entire contents of the vial.
Replace the needle with the yellow mark by the injection needle with the grey mark (27-gauge).
Invert the syringe and push the plunger until all air bubbles have been expelled.
Choose an injection site in the lower abdominal area, preferably around, but staying at least one inch away from the navel. Choose a different injection site each day to minimize local irritation. Use a second alcohol swab to clean the skin at the injection site and allow alcohol to dry. Gently pinch up the skin surrounding the site of injection.
Inject the prescribed dose as directed by your doctor, nurse or pharmacist.
Use the syringe and needles only once. Dispose of the syringe and needles properly after use. If available, use a medical waste container for disposal.
Warnings & precautions
Do not take this medicine if: Cetrorelix acetate is contraindicated under the following conditions:
Hypersensitivity to cetrorelix acetate, extrinsic peptide hormones or mannitol.
Known hypersensitivity to GnRH or any other GnRH analogs.
Known or suspected pregnancy, and lactation .
Severe renal impairment
Cases of hypersensitivity reactions, including anaphylactoid reactions with the first dose, have been reported during post-marketing surveillance . A severe anaphylactic reaction associated with cough, rash, and hypotension, was observed in one patient after seven months of treatment with cetrorelix acetate (10 mg/day) in a study for an indication unrelated to infertility.
Special care should be taken in women with signs and symptoms of active allergic conditions or known history of allergic predisposition. Treatment with cetrorelix acetate is not advised in women with severe allergic conditions.
Prior to therapy with cetrorelix acetate, patients should be informed of the duration of treatment and monitoring procedures that will be required. The risk of possible adverse reactions should be discussed . Cetrorelix acetate should not be prescribed if a patient is pregnant.
If cetrorelix acetate is prescribed to patients for self-administration, information for proper use is given in the Patient Leaflet .
After the exclusion of preexisting conditions, enzyme elevations (ALT, AST, GGT, alkaline phosphatase) were found in 1-2% of patients receiving cetrorelix acetate during controlled ovarian stimulation. The elevations ranged up to three times the upper limit of normal. The clinical significance of these findings was not determined.
During stimulation with human menopausal gonadotropin, cetrorelix acetate had no notable effects on hormone levels aside from inhibition of LH surges.
No formal drug interaction studies have been performed with cetrorelix acetate. …
Cetrorelix side effects
The safety of cetrorelix acetate in 949 patients undergoing controlled ovarian stimulation in clinical studies was evaluated. Women were between 19 and 40 years of age (mean: 32). 94.0% of them were Caucasian. Cetrorelix acetate was given in doses ranging from 0.1 mg to 5 mg as either a single or multiple dose.
Table 3 shows systemic adverse events, reported in clinical studies without regard to causality, from the beginning of cetrorelix acetate treatment until confirmation of pregnancy by ultrasound at an incidence ≥ 1% in cetrorelix acetate treated subjects undergoing COS.
* Intensity moderate or severe, or WHO Grade II or III, respectively
(WHO preferred term) | Cetrorelix Acetate N=949 % (n)
Ovarian Hyperstimulation Syndrome* | 3.5 (33)
Nausea | 1.3 (12)
Headache | 1.1 (10)
Local site reactions (e.g. redness, erythema, bruising, itching, swelling, and pruritus) were reported. Usually, they were of a transient nature, mild intensity and short duration. During post-marketing surveillance, cases of mild to moderate Ovarian Hyperstimulation syndrome and cases of hypersensitivity reactions including anaphylactoid reactions have been reported.
Two stillbirths were reported in Phase 3 studies of cetrorelix acetate.
Clinical follow-up studies of 316 newborns of women administered cetrorelix acetate were reviewed. One infant of a set of twin neonates was found to have anencephaly at birth and died after four days. The other twin was normal. …
About this medicine
Cetrorelix Acetate for Injection is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. Cetrorelix acetate is an analog of native GnRH with substitutions of amino acids at positions 1, 2, 3, 6, and 10. The molecular formula is Acetyl-D-3-(2′-naphtyl)-alanine-D-4-chlorophenylalanine-D-3-(3′-pyridyl)-alanine-L-serine-L-tyrosine-D-citruline-L-leucine-L-arginine-L-proline-D-alanine-amide, and the molecular weight is 1431.06, calculated as the anhydrous free base. The structural formula is as follows:
Cetrorelix Acetate for Injection 0.25 mg is a sterile lyophilized powder intended for subcutaneous injection after reconstitution with Sterile Water for Injection, that comes supplied in a 1 mL prefilled syringe. Each vial of Cetrorelix Acetate for Injection 0.25 mg contains 0.26-0.27 mg cetrorelix acetate, equivalent to 0.25 mg cetrorelix, and 54.80 mg mannitol.
How it works: GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 9b3057ac-6cac-4509-a355-df76247b992c. Read the full official label on DailyMed.